Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.

RPEP-160632026Sass, Marie R; Klausen, Mette Kruse; Schwarz, Christine R; Rasmussen, Line; Giver, Malte E B; Hviid, Malthe; Schilling, Christoffer; Zamorski, Alexandra; Jensen, Andreas; Gefke, Maria; Storgaard, Heidi; Oturai, Peter S; Kjaer, Andreas; Hartmann, Bolette; Holst, Jens J; Ekstrøm, Claus T; Vinberg, Maj; Correll, Christoph U; Vilsbøll, Tina; Fink-Jensen, Anders

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.

JAMA psychiatry, 83(2), 128-138

View on PubMed ↗Publisher’s paper ↗

Citation

Sass, Marie R; Klausen, Mette Kruse; Schwarz, Christine R; Rasmussen, Line; Giver, Malte E B; Hviid, Malthe; Schilling, Christoffer; Zamorski, Alexandra; Jensen, Andreas; Gefke, Maria; Storgaard, Heidi; Oturai, Peter S; Kjaer, Andreas; Hartmann, Bolette; Holst, Jens J; Ekstrøm, Claus T; Vinberg, Maj; Correll, Christoph U; Vilsbøll, Tina; Fink-Jensen, Anders. (2026). Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.. JAMA psychiatry, 83(2), 128-138. https://doi.org/10.1001/jamapsychiatry.2025.3639